STOCK TITAN

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Anavex Life Sciences Corp. (Nasdaq: AVXL), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024 in New York City. Christopher U. Missling, PhD, President and CEO of Anavex, will present on Monday, September 9, 2024, at 11:30 a.m. ET at the Lotte New York Palace.

The presentation will be available via audio webcast on the company's website. Additionally, Dr. Missling will participate in a panel discussion on 'Non-Amyloid-Targeted Approaches in Treatment of Alzheimer's Disease' on September 10, 2024 at 2:00 p.m. ET. Anavex focuses on developing therapeutics for various CNS diseases, including Alzheimer's, Parkinson's, and Rett syndrome.

Anavex Life Sciences Corp. (Nasdaq: AVXL), una società biofarmaceutica in fase clinica, ha annunciato la sua partecipazione al 26° Convegno Annuale di Investimenti Globali H.C. Wainwright che si terrà dal 9 all'11 settembre 2024 a New York City. Christopher U. Missling, PhD, Presidente e CEO di Anavex, presenterà lunedì 9 settembre 2024, alle 11:30 a.m. ET presso il Lotte New York Palace.

La presentazione sarà disponibile tramite webcast audio sul sito web dell'azienda. Inoltre, il Dr. Missling parteciperà a una discussione di panel su 'Approcci Non-Amyloidi nel Trattamento della Malattia di Alzheimer' il 10 settembre 2024 alle 2:00 p.m. ET. Anavex si concentra sullo sviluppo di terapie per varie malattie del SNC, inclusi Alzheimer, Parkinson e la sindrome di Rett.

Anavex Life Sciences Corp. (Nasdaq: AVXL), una empresa biofarmacéutica en etapa clínica, anunció su participación en la 26ª Conferencia Anual de Inversiones Globales H.C. Wainwright que se llevará a cabo del 9 al 11 de septiembre de 2024 en la ciudad de Nueva York. Christopher U. Missling, PhD, Presidente y CEO de Anavex, presentará el lunes 9 de septiembre de 2024, a las 11:30 a.m. ET en el Lotte New York Palace.

La presentación estará disponible a través de un webcast de audio en el sitio web de la empresa. Además, el Dr. Missling participará en una discusión de panel sobre 'Enfoques no dirigidos a la amiloide en el tratamiento de la enfermedad de Alzheimer' el 10 de septiembre de 2024 a las 2:00 p.m. ET. Anavex se centra en desarrollar terapias para varias enfermedades del SNC, incluidas Alzheimer, Parkinson y el síndrome de Rett.

Anavex Life Sciences Corp. (Nasdaq: AVXL), 임상 단계의 생물 의약품 회사가 2024년 9월 9일부터 11일까지 뉴욕시에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. Christopher U. Missling, PhD는 Anavex의 회장이자 CEO로, 2024년 9월 9일 월요일 오전 11시 30분 ET에 Lotte New York Palace에서 발표를 진행할 예정입니다.

발표는 회사 웹사이트에서 오디오 웹캐스트를 통해 제공될 예정입니다. 또한, Missling 박사는 '알츠하이머병 치료를 위한 비아밀로이드 타겟 접근법'에 대한 패널 토론에도 참여할 예정이며, 이는 2024년 9월 10일 오후 2시 ET에 진행됩니다. Anavex는 알츠하이머, 파킨슨병 및 레트 증후군을 포함한 다양한 CNS 질환에 대한 치료제를 개발하는 데 중점을 두고 있습니다.

Anavex Life Sciences Corp. (Nasdaq: AVXL), une société bio-pharmaceutique en phase clinique, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale des Investissements H.C. Wainwright qui se tiendra du 9 au 11 septembre 2024 à New York. Christopher U. Missling, PhD, Président et CEO d'Anavex, fera une présentation le lundi 9 septembre 2024 à 11h30 ET au Lotte New York Palace.

La présentation sera disponible en streaming audio sur le site web de l'entreprise. De plus, le Dr. Missling participera à une discussion de panel sur 'Approches non ciblées sur l'amiloïde dans le traitement de la maladie d'Alzheimer' le 10 septembre 2024 à 14h00 ET. Anavex se concentre sur le développement de thérapies pour diverses maladies du SNC, y compris Alzheimer, Parkinson et le syndrome de Rett.

Anavex Life Sciences Corp. (Nasdaq: AVXL), ein biopharmazeutisches Unternehmen in klinischer Phase, gab seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright vom 9. bis 11. September 2024 in New York City bekannt. Christopher U. Missling, PhD, Präsident und CEO von Anavex, wird am Montag, den 9. September 2024, um 11:30 Uhr ET im Lotte New York Palace präsentieren.

Die Präsentation wird über einen Audiowebcast auf der Webseite des Unternehmens verfügbar sein. Darüber hinaus wird Dr. Missling an einer Podiumsdiskussion über 'Nicht-Amyloid-targetierte Ansätze zur Behandlung der Alzheimer-Krankheit' am 10. September 2024 um 14:00 Uhr ET teilnehmen. Anavex konzentriert sich auf die Entwicklung von Therapeutika für verschiedene ZNS-Erkrankungen, darunter Alzheimer, Parkinson und das Rett-Syndrom.

Positive
  • None.
Negative
  • None.

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11, 2024 in New York City.

The presentation will take place on Monday, September 9, 2024, at 11:30 a.m. ET at the Lotte New York Palace in New York, NY. An audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. A replay of the session will be available later that day.

In addition, Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a panel titled “Non-Amyloid-Targeted Approaches in Treatment of Alzheimer’s Disease” taking place September 10, 2024 at 2:00 p.m. ET at the Lotte New York Palace in New York, NY.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com


FAQ

When is Anavex Life Sciences (AVXL) presenting at the H.C. Wainwright Global Investment Conference 2024?

Anavex Life Sciences (AVXL) is presenting on Monday, September 9, 2024, at 11:30 a.m. ET at the Lotte New York Palace in New York City.

What panel is Anavex's CEO participating in at the H.C. Wainwright conference?

Christopher U. Missling, PhD, CEO of Anavex, will participate in a panel titled 'Non-Amyloid-Targeted Approaches in Treatment of Alzheimer's Disease' on September 10, 2024 at 2:00 p.m. ET.

How can investors access Anavex's (AVXL) presentation at the H.C. Wainwright conference?

Investors can access an audio webcast of Anavex's presentation through the Investors section of the company's website at www.anavex.com. A replay will be available later that day.

What diseases does Anavex Life Sciences (AVXL) focus on in its drug development?

Anavex Life Sciences (AVXL) focuses on developing therapeutics for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental and neurodegenerative diseases, rare diseases including Rett syndrome, and other central nervous system (CNS) diseases.

Anavex Life Sciences

NASDAQ:AVXL

AVXL Rankings

AVXL Latest News

AVXL Stock Data

676.67M
82.21M
3.05%
32.08%
22.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NEW YORK